The 14th five year plan for the development of traditional Chinese medicine comprehensively promotes the development of the industry and maintains the “optimistic” rating. On March 29, the general office of the State Council issued the 14th five year plan for the development of traditional Chinese medicine (hereinafter referred to as the “14th five year plan”), which puts forward development requirements on the basis of accelerating the improvement of the top-level design for the development of traditional Chinese medicine in the 13th five year plan, continuously optimizing the policy environment and increasing support, Put forward development goals for traditional Chinese medicine services, talent team, inheritance and innovation and high-quality industrial development, so as to promote the high-quality development of traditional Chinese medicine industry. We believe that the 14th five year plan will comprehensively promote the healthy and long-term development of traditional Chinese medicine from the aspects of clinical research and development, medical service, traditional Chinese medicine planting, payment and drainage.
Benefit sectors: innovative traditional Chinese medicine, traditional Chinese medicine chain, rehabilitation institutions and equipment, traditional Chinese medicine planting and traditional Chinese medicine products. From the perspective of subdivision sectors, we believe that innovative traditional Chinese medicine, traditional Chinese medicine chain, rehabilitation institutions, rehabilitation equipment, traditional Chinese medicine planting, traditional Chinese medicine products and other sectors benefit. In terms of innovative traditional Chinese medicine, the 14th five year plan emphasizes tackling key problems in key areas compared with the 13th five year plan. At the same time, strengthening the cooperation between traditional Chinese medicine hospitals, enterprises and scientific research institutions is conducive to traditional Chinese medicine innovative medicine enterprises to enrich their innovative resources and accelerate the progress of new drug research and development; Optimizing the registration management of traditional Chinese medicine preparations and speeding up the collection of key information of prescriptions are conducive to speeding up the approval process of new traditional Chinese medicine drugs. In terms of TCM chain, the 14th five year plan encourages qualified TCM professionals and technicians to set up TCM clinics, significantly increasing their support compared with the 13th five year plan. Gushengtang, Chinese traditional medicine and other enterprises carrying out TCM clinics are expected to speed up the layout of relevant businesses with policy support. In terms of rehabilitation, the plan proposes to lay out the rehabilitation center of traditional Chinese medicine, and the State supports the rehabilitation chain organized by private institutions. The construction of rehabilitation hospitals and rehabilitation departments will increase the demand for rehabilitation equipment and facilitate the business expansion of rehabilitation equipment manufacturing and sales enterprises. In terms of traditional Chinese medicine planting, the 14th five year plan has broadened the development space of traditional Chinese medicine planting industry, benefiting traditional Chinese medicine manufacturers with traditional Chinese medicine planting layout, including Chinese traditional medicine, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) , Beijing Tongrentang Co.Ltd(600085) , Kpc Pharmaceuticals Inc(600422) , etc. The strong support of payment end and medical insurance end will promote the growth of demand for traditional Chinese medicine. On the channel side, the expansion of the Internet and overseas channels is conducive to the expansion of business coverage of traditional Chinese medicine enterprises. Since the outbreak of covid-19 pneumonia, traditional Chinese medicine has fully participated in the epidemic prevention, control and treatment. The combination of traditional Chinese and Western medicine will further promote the growth of the sales scale of traditional Chinese medicine.
Recommended and beneficial objects
Innovative Chinese medicine sector: recommended targets: Tasly Pharmaceutical Group Co.Ltd(600535) , Guiyang Xintian Pharmaceutical Co.Ltd(002873) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ; Beneficiary objects: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) , Youcare Pharmaceutical Group Co.Ltd(688658) .
Chain of traditional Chinese medicine: beneficiaries: gushengtang, Chinese traditional medicine.
Chinese herbal medicine planting sector: recommended target: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) ; Beneficiary targets: Chinese traditional medicine, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Tibet Rhodiola Pharmaceutical Holding Company(600211) , Henan Taloph Pharmaceutical Stock Co.Ltd(600222) , Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) .
Oral Chinese medicine: recommended targets: Henan Lingrui Pharmaceutical Co.Ltd(600285) , Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) . Beneficiary objects: China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , Jiuzhitang Co.Ltd(000989) , Jianmin Pharmaceutical Group Co.Ltd(600976) , Hubei Jumpcan Pharmaceutical Co.Ltd(600566) , Yunnan Baiyao Group Co.Ltd(000538) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Maanshan Iron & Steel Company Limited(600808) 5 .
Rehabilitation machinery: recommended target: Xiangyumedicalco.Ltd(688626) .
Risk tip: product R & D is less than the expected risk, expansion is less than the expected risk, and marketing is less than the expected risk.
